# Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

> **NCT04417621** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** LXH254
- **DRUG:** LTT462
- **DRUG:** Trametinib
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT04417621
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-30
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417621, "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04417621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*